Safety and Biomarker Study of EPI-589 in Participants With Amyotrophic Lateral Sclerosis (ALS)
NCT02460679
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
19
Enrollment
INDUSTRY
Sponsor class
Conditions
Amyotrophic Lateral Sclerosis
Interventions
DRUG:
EPI-589
Sponsor
PTC Therapeutics